Pharmaceuticals Global News & Press Release Distribution

Pharmaceuticals

All
APAC

IASO Bio Presented New Data of FUCASO® (Equecabtagene Autoleucel) for the Treatment of High-risk Newly Diagnosed Multiple Myeloma in Oral Presentation at EHA 2024

SHANGHAI and NANJING, China and SAN JOSE, Calif., June 15, 2024 /PRNewswire/ -- IASO biotechnology ("IASO Bio"), a biopharmaceutical company engaged in discovering, developing, manufacturing and marketing innovative cell therapies and antibody products, presented clinical data on the use of Equec...

2024-06-15 22:30 4872

CARsgen Presents First-in-human Results of GPRC5D Targeting CAR-T CT071 at EHA 2024

SHANGHAI, June 15, 2024 /PRNewswire/ -- CARsgen Therapeutics Holdings Limited (Stock Code: 2171.HK), a company focused on innovative CAR T-cell therapies for the treatment of hematologic malignancies and solid tumors, announces that the initial results from the ongoing first-in-human study of CT0...

2024-06-15 20:50 4902

Latest Updates of Viva Biotech's Portfolio Companies

HONG KONG, June 12, 2024 /PRNewswire/ -- Even with the ever-changing situation, technological innovation is still the most critical component for biopharmaceutical companies' long-term development. This continuous innovation keeps companies up to date and promotes the evolution of R&D and the suc...

2024-06-12 19:51 3154

2024ASCO｜Memorial Sloan Kettering Cancer Center (MSK)'s Prof. Wungki Park Unveils Precision Targeting of TF in Pancreatic Cancer, Signaling ADC Drug Innovations

Introduction: ADC Drug Breakthrough Targets TF in Pancreatic Cancer CHICAGO, June 12, 2024 /PRNewswire/ -- The 2024 American Society of Clinical Oncology (ASCO) Annual Meeting, held inChicago from May 31 to June 4, shone a spotlight on MRG004A, a novel antibody-drug conjugate (ADC) designed to tr...

2024-06-12 19:31 2580

Ono Announces Results of Tender Offer to Acquire Deciphera Pharmaceuticals and Completion of Acquisition of Deciphera (a Wholly Owned Subsidiary of Ono)

OSAKA, Japan and WALTHAM, Mass., June 11, 2024 /PRNewswire/ -- Ono Pharmaceutical, Co., Ltd. (Chairman and CEO:Gyo Sagara, "Ono") today announced that it has successfully completed the tender offer, previously announced on April 30, 2024 to acquire all outstanding shares of common stock of a US b...

2024-06-11 20:30 2520

111, Inc., Scrianen Announce Strategic Direct Supply Partnership to Expand Nationwide Reach and Improve Drug Accessibility

SHANGHAI, June 11, 2024 /PRNewswire/ -- 111, Inc. ("111" or the "Company") (NASDAQ: YI), a leading tech-enabled healthcare platform company committed to reshaping the value chain of healthcare industry by digitally empowering the upstream and downstream inChina, announced that the Company has ent...

2024-06-11 15:57 4534

Gannex Announces Poster Presentation of Positive Interim 12-Week Results from Phase II Clinical Trial of ASC41 in Patients with Biopsy-Confirmed MASH at EASL CONGRESS 2024

--Up to 68.2% mean relative reduction in liver fat content from baseline among biopsy-confirmed metabolic dysfunction-associated steatohepatitis (MASH) patients receiving 12-week treatment of ASC41 --Significant and clinically meaningful reductions in liver fat, alanine aminotransferase(ALT), as...

2024-06-11 08:10 3263

Kangpu Biopharmaceuticals to Present Results from Phase 2a of KPG-818 in SLE at EULAR 2024

HEFEI, China, June 10, 2024 /PRNewswire/ -- Kangpu Biopharmaceuticals today announced that a poster tour presentation highlighting the Phase 2a clinical data of KPG-818 in patients with Systemic Lupus Erythematosus (SLE) will be presented at the upcoming Annual European Congress of Rheumatology E...

2024-06-10 20:00 3138

FDA Grants Fast Track Designation to GCBP and Novel Pharma's GC1130A

* FDA's Fast Track designation speeds up the development of new biologic drugs for rare diseases YONGIN, South Korea, June 10, 2024 /PRNewswire/ -- GC Biopharma (006280. KS) and Novel Pharma have announced that the U.S. FDA has granted Fast Track Designation for their jointly developed MPSIIIA ...

2024-06-10 16:18 3648

J INTS BIO, ASCO 2024 - JIN-A02 showed tumor reductions including brain metastasis in the ongoing first-in-human, dose-finding Phase 1 clinical study

SEOUL, South Korea, June 10, 2024 /PRNewswire/ -- J INTS BIO provided an update of its ongoing Phase 1 clinical study of JIN-A02, a 4th generation EGFR-TKI for NSCLC treatment, during the 3rd of June poster session of the 2024 American Society of Clinical Oncology (ASCO) Annual Meeting held at Mc...

2024-06-10 13:56 2536

J INTS BIO, ASCO 2024 - JIN-A02 showed tumor reductions including brain metastasis in the ongoing first-in-human, dose-finding Phase 1 clinical study

Qilu Pharmaceutical's Three Clinical Studies on Cancer Immunotherapy Presented at ASCO 2024

JINAN, China, June 6, 2024 /PRNewswire/ -- The 2024 American Society of Clinical Oncology (ASCO) Annual Meeting convened fromMay 31 to June 4, 2024 in Chicago, USA, adopting a hybrid format. Among the presented works, three clinical studies from Qilu Pharmaceutical were selected for poster sessio...

2024-06-07 14:51 2928

Qilu Pharmaceutical's Three Clinical Studies on Cancer Immunotherapy Presented at ASCO 2024

MicuRx: Successful Completion of Phase I Clinical Trial for Self-Developed MRX-8 Antibacterial Drug in China

* According to the World Health Organization (WHO), millions of patients face treatment difficulties or even life-threatening conditions due to resistant bacterial infections each year. * MRX-8 not only shows excellent safety and tolerability but also demonstrates strong antibacterial activit...

2024-06-06 19:52 2980

I-Mab Appoints Phillip Dennis, MD, PhD, as Chief Medical Officer

ROCKVILLE, Md., June 6, 2024 /PRNewswire/ -- I-Mab (NASDAQ: IMAB) (the "Company"), a U.S.-based, global biotech company, exclusively focused on the development and potential commercialization of highly differentiated immunotherapies for the treatment of cancer, today announced the appointment of...

2024-06-06 19:00 2730

Oricell Presented Long-term Follow-up Data of OriCAR-017 in RRMM at 2024 ASCO Annual Meeting, Highlighting the Sustained Efficacy of GPRC5D CAR-T Therapy

SHANGHAI and ROSELAND, N.J., June 5, 2024 /PRNewswire/ -- Oricell Therapeutics, a pioneering clinical-stage biopharmaceutical company, has presented the two-year long-term follow-up results of OriCAR-017, an open-label Phase I study evaluating GPRC5D-targeted CAR-T therapy in patients with relaps...

2024-06-05 19:59 4578

FDA Approved Phase II/III Clinical Study of KPG-121 in Combination with Abiraterone as a First Line Treatment for mCRPC

HEFEI, China, June 5, 2024 /PRNewswire/ -- Kangpu Biopharmaceuticals today announced that the U.S. Food and Drug Administration (FDA) has recently approved a Phase II/III clinical trial of KPG-121 in combination with Abiraterone for a first-line treatment of metastatic castration resistant prost...

2024-06-05 19:00 3046

GC Genome Highlights Promising New Approach for Non-invasive Colorectal Cancer Detection at ASCO 2024

YONGIN, South Korea, June 5, 2024 /PRNewswire/ -- GC Genome Corporation, a leading diagnostics company, presented new data from its AI-based liquid biopsy platform for non-invasive colorectal cancer (CRC) detection at the 2024 American Society of Clinical Oncology (ASCO) Annual Meeting. Conducted...

2024-06-05 14:00 3005

Live from ASCO 2024 | Oral Report Released Latest Data of Olverembatinib in SDH-Deficient GIST, Including a CBR of 92.3%

SUZHOU, China and ROCKVILLE, Md., June 4, 2024 /PRNewswire/ -- Ascentage Pharma (6855.HK), a global biopharmaceutical company engaged in developing novel therapies for cancer, chronic hepatitis B (CHB), and age-related diseases, announced today that it has released updated clinical data of olvere...

2024-06-05 11:46 2784

Live from ASCO 2024 | Ascentage Pharma Releases Updated Data Showing Promising Efficacy and Safety of Lisaftoclax in Patients with WM

SUZHOU, China, and ROCKVILLE, Md., June 4, 2024 /PRNewswire/ -- Ascentage Pharma (6855.HK), a global biopharmaceutical company engaged in developing novel therapies for cancer, chronic hepatitis B (CHB), and age-related diseases, announced today that it has released updated results from a global,...

2024-06-05 11:31 2598

CARsgen Presents Updated Results on Satri-cel in Nature Medicine and at 2024 ASCO

SHANGHAI, June 4, 2024 /PRNewswire/ -- CARsgen Therapeutics Holdings Limited (Stock Code: 2171.HK), a company focused on innovative CAR T-cell therapies for the treatment of hematologic malignancies and solid tumors, announces that the final follow-up results of the investigator-initiated trial C...

2024-06-04 20:50 2775

GCBP Sponsors 2024 Spring Symposium for KASBP and Present Research Findings

YONGIN, South Korea, June 4, 2024 /PRNewswire/ -- GC Biopharma announced that it will attend 2024 Spring Symposium of the Korean American Society in Biotech and Pharmaceuticals (KASBP) onJune 7-8th at Waltham, Massachusetts as a sponsor to share keynote presentation, present Korean Scientist Awar...

2024-06-04 13:00 2570

1 ... 82 83 848586 87 88 ... 166